Casopís lékar̆ů c̆eských
-
Rare diseases are defined as those affected less than five in every 10 000 person in European Union. The purpose of this paper is to present activities, which make possible to stimulate research development and marketing of appropriate medicine for tretment of rare disease, named "Orphan" medicinal products. EU "Orphan" medicinal products legislation which entered into force in April 2000 is described. ⋯ Those incentives to industry are described, which are already five years very well implemented oh the European level mostly on the pre-authorisation phase of "Orphan" medicinal products development, but also in the registration process as well as the post-authorisation phase. Finaly, the first twenty "Orphan" medicinal products, which have been given positive opinion in the Community for the grant of a marketing authorisation till April 2005 are mentioned in this work. The real availability of "Orphan" medicinal products in the particular EU member states is analysed.
-
Casopís lékar̆ů c̆eských · Jan 2006
Case Reports[Methylene blue in the therapy of vasoplegic syndrome after cardiac surgery procedure].
Vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass is severe complication with high morbidity and mortality. Without appropriate therapy the syndrome advances to the shock state with subsequent multiorgan failure. ⋯ Methylene blue is other therapeutic option. The case of successful application of methylene blue for the treatment of vasoplegic syndrome is presented.
-
Casopís lékar̆ů c̆eských · Jan 2006
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by an abnormal fusion gene BCR-ABL. BCR-ABL encodes a constitutively active Bcr-Abl tyrosine kinase, which is required and sufficient for cellular transformation. Bcr-Abl is, therefore, an ideal target for pharmacotherapy. ⋯ Src kinases). Standard cytogenetics as well as assay evaluating the phosphorylation status of Bcr-Abl substrate and/or sequencing of Abl kinase transcript can be used to test the mechanism of resistance. Treatment of patients can be re-evaluated on the basis of the status of IM resistance.
-
Casopís lékar̆ů c̆eských · Jan 2005
[Telephone hotlines as a part of complex services for tobacco dependence treatment].
Telephone quitlines for smoking cessation should be included into the available tobacco dependence treatment and should be included into smoking cessation guidelines. Telephone quitlines does not mean only the help to the calling smoker, but also can increase the number of quit attempts in the general population. ⋯ Quitlines are economically effective, although the most expensive form - individual counselling - should be reserved for those really willing to stop. Quitlines should be given governmental financial support (compared to other medical interventions, any smoking cessation treatment is economically more cost effective).
-
Casopís lékar̆ů c̆eských · Jan 2005
Review[Treatment of the unresectable non small cell lung carcinoma].
In recent years, treatment of the locally advanced unresectable Non Small Cell Lung Cancer (NSCLC) has evolved from the radiotherapy alone to sequential therapy settings with induction chemotherapy followed by radiotherapy. During recent years, concomitant chemoradiotherapy has become the standard treatment for these patients. The addition of chemotherapy during the course of radiotherapy provides better locoregional control of the disease by killing the radioresistant cells, inhibition of the reparation processes in the sublethally damaged cells and accumulation of the cells in the G2/M phase, when the cells are sensitive to radiation. ⋯ When comparing survival time by meta-analysis, significantly longer survival time of the patients treated with gemcitabine combination was found in comparison with other treatment. Similarly, the progression-free survival is significantly longer in the patients treated with gemcitabine containing regimen. This data has proven good clinical efficacy of gemcitabine in the first-line therapy of advanced NSCLC.